Genoway SA
PAR:ALGEN
Genoway SA
Operating Income
Genoway SA
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Genoway SA
PAR:ALGEN
|
Operating Income
€1.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
14%
|
CAGR 10-Years
50%
|
|
Valneva SE
PAR:VLA
|
Operating Income
-€126.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Nanobiotix SA
PAR:NANO
|
Operating Income
-€26.8m
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-13%
|
|
Innate Pharma SA
PAR:IPH
|
Operating Income
-€12.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-16%
|
|
G
|
Genfit SA
PAR:GNFT
|
Operating Income
-€26.7m
|
CAGR 3-Years
30%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-10%
|
Abivax SA
PAR:ABVX
|
Operating Income
-€127.4m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
See Also
What is Genoway SA's Operating Income?
Operating Income
1.7m
EUR
Based on the financial report for Jun 30, 2023, Genoway SA's Operating Income amounts to 1.7m EUR.
What is Genoway SA's Operating Income growth rate?
Operating Income CAGR 10Y
50%
Over the last year, the Operating Income growth was 213%.